The hypothetical cessation of all PSA testing for asymptomatic men in 2015 would result in a substantial decrease, RR 0.72 (95% MCI 0.72–0.73), of prostate cancer incidence compared with the current testing rates over 20 years as well as no overdiagnosis of asymptomatic men. Here, KLK3 is linked to Familial prostate cancer.